Pcn178 - Cost-Effectiveness of Pembrolizumab as Second-Line Treatment for Patients With Advanced Urothelial Cancer in France
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.261
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV